E

Egetis Therapeutics AB

Late-stage rare-disease drug development and commercialization

Director, Clinical Development

Biology & BiotechConfirmed live in the last 24 hours
Full-timeRemote in SwedenNo salary listed

About the Job

Requirements

  • A medical degree (MD or equivalent) is required.
  • At least 5 years of experience as a study physician or medical monitor in biopharmaceutical clinical development is required.
  • Working knowledge of ICH-GCP, global regulatory requirements (FDA, EMA, and ICH), pharmacovigilance principles, and clinical trial methodology, including estimands and endpoint selection, is required.
  • Experience in interventional clinical trials, ideally including late-stage development, is required.
  • Experience in protocol authoring, medical data review, safety review, and clinical study report and regulatory document preparation is required.
  • Strong clinical and scientific judgment, with rigorous attention to accuracy and data integrity, is required.
  • Excellent written and verbal communication and the ability to translate complex clinical data for expert and non-expert audiences are required.
  • A collaborative, cross-functional mindset and the ability to influence without direct authority are required.
  • Sound decision-making under uncertainty and a patient-safety-first orientation are required.
  • The ability to stay organized and manage multiple priorities in a fast-paced, growing organization is required.
  • A hands-on, pragmatic approach and flexibility to contribute beyond defined role boundaries as organizational needs evolve are required.

Responsibilities

  • Provide medical and scientific input into the study concept, target product profile, and clinical development plan for assigned indications.
  • Author or co-author clinical sections of study protocols, including objectives, endpoints, eligibility criteria, dosing rationale, and estimands, ensuring scientific and ethical integrity of the design.
  • Contribute to protocol synopses, amendments, and schedules of activities, ensuring feasibility and alignment with regulatory expectations.
  • Provide clinical input into case report form design, edit checks, data management plans, and monitoring plans.
  • Act as study physician and medical monitor, providing day-to-day medical guidance to sites, Clinical Operations, and the contract research organization throughout study conduct.
  • Review eligibility questions, protocol deviations, and dose-modification decisions, and respond to investigator medical queries in a timely manner.
  • Provide medical input into monitoring strategy, site selection, investigator engagement, and study start-up activities.
  • Support recruitment and retention through medical education of sites and development of study-specific medical guidance and frequently asked questions.
  • Serve as medical reviewer for study-level adverse events and serious adverse events, conducting ongoing medical review of safety data in collaboration with Pharmacovigilance.
  • Contribute to safety management plans, benefit-risk assessment, causality and expectedness assessment, and study signal detection.
  • Support preparation of safety sections of the Investigator's Brochure, DSUR, and aggregate safety reports, and contribute to Data Monitoring Committee activities where applicable.
  • Escalate emerging safety findings to the Chief Medical Officer and benefit-risk or safety governance bodies.
  • Lead ongoing medical and clinical data review to ensure data quality, consistency, and integrity throughout the study.
  • Provide medical input into the statistical analysis plan and participate in database lock, unblinding, and interpretation of study results.
  • Interpret efficacy and safety findings in clinical and scientific context and translate them into clear conclusions for internal and external audiences.
  • Author or provide senior medical review of key study documents, including clinical study reports, informed consent templates, and clinical narratives.
  • Contribute clinical content to regulatory submissions, including IND/IMPD, briefing books, and MAA/NDA modules, and to responses to health-authority questions.
  • Support abstracts, manuscripts, and congress presentations arising from the study, ensuring scientific accuracy and compliance with publication standards.
  • Ensure study conduct complies with ICH-GCP, applicable FDA and EMA regulations, the Declaration of Helsinki, and company standard operating procedures.
  • Provide medical input into interactions with regulatory authorities and ethics committees or institutional review boards, and support inspection readiness.
  • Ensure study-level activities uphold the ethical and scientific integrity of the development program and core labeling texts.
  • Partner with Clinical Operations, Biostatistics, Regulatory Affairs, Pharmacovigilance, Medical Affairs, and CMC to deliver studies on time, within budget, and to quality standards.
  • Engage key opinion leaders, investigators, scientific advisors, and patient organizations; organize and synthesize expert and advisory-board input into study strategy.
  • Provide medical oversight of contract research organizations and specialty vendors, such as central laboratories, ECG, imaging, and electronic patient-reported or clinical outcome assessment vendors, at the study level.
  • Contribute to feasibility, timelines, budget, and risk management for assigned studies.

Desired Qualifications

  • Specialist training and/or clinical practice experience, such as endocrinology, pediatrics, internal medicine, or a relevant rare-disease field, is desirable.
  • Rare-disease and/or endocrinology experience is an advantage.
  • Familiarity with pediatric development is desirable.

About the Company

Egetis Therapeutics AB

Late-stage rare-disease drug development and commercialization

Egetis Therapeutics AB develops and commercializes medicines for rare diseases, focusing on late-stage assets. Its lead candidate, Emcitate (tiratricol), treats MCT8 deficiency and has EU approval with a German launch, plus a rolling FDA NDA started in 2025. A second asset, Aladote (calmangafodipir), targets acetaminophen-induced liver injury and holds US/EU orphan designations, with a pivotal trial planned after Emcitate submissions. The company aims to sell directly in Europe and North America while out-licensing in other regions, differentiate itself by concentrating on orphan diseases with clear unmet needs, and pursue regulatory approvals and partnerships to bring therapies to patients.

Company size
51-200
Company stage
IPO
Headquarters
Stockholms kommun, Sweden
Founded
2006

Recently Posted Jobs

Explore more opportunities at Egetis Therapeutics AB

See more jobs